GSK Agreement to Acquire RAPT Therapeutics Yesterday,  January 20, GSK (GSK) announced that it has entered a definitive agreement to acquire RAPT Therapeutics (RAPT) a California-based, clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing . . . This content is for paid subscribers. Please click here to subscribe or here to log in.